Difference between revisions of "Profiles"
| (2 intermediate revisions by the same user not shown) | |||
| Line 14: | Line 14: | ||
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | :* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | ||
| + | *[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2016-06-01]] (''Closed Sept 2016'') | ||
| + | :*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]] | ||
| + | :*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]] | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
| Line 27: | Line 30: | ||
*[[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (''Closed on September 15, 2017'') | *[[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (''Closed on September 15, 2017'') | ||
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf| QIBA MRE Profile 2017-08-15]] (''Closed on September 15, 2017'') | *[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf| QIBA MRE Profile 2017-08-15]] (''Closed on September 15, 2017'') | ||
| − | *[[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (''Closed on August 25, 2017'') | + | *[[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (''Closed on August 25, 2017'') |
| − | |||
| − | |||
| − | |||
| − | |||
==Format for Citing Profiles== | ==Format for Citing Profiles== | ||
Revision as of 21:50, 8 December 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
- QIBA Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2016-06-01 (Closed Sept 2016)
Stage 1: Public Comment Profiles
The following Profiles are open for Public Comment:
- QIBA fMRI Profile 2017-06-19 Open until December 31, 2017 (extended)
Please submit all public comments through the following online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; you may submit additional forms as necessary)
Public Comment closed for the following Profiles (comment resolution is currently underway):
- QIBA PET Amyloid Profile 2017-06-15 (Closed on September 15, 2017)
- QIBA MRE Profile 2017-08-15 (Closed on September 15, 2017)
- DWI Profile 2017-04-27 (Closed on August 25, 2017)
Format for Citing Profiles
Note to users: When referencing QIBA Profile documents, please use the following format:
Specific QIBA Biomarker Committee. * Specific Profile Title, * Quantitative Imaging Biomarkers Alliance. * Version. * Profile Stage. * QIBA, * Date. * Available from: URL
Format example:
QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)